1. Home
  2. GPCR vs AGX Comparison

GPCR vs AGX Comparison

Compare GPCR & AGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GPCR
  • AGX
  • Stock Information
  • Founded
  • GPCR 2016
  • AGX 1961
  • Country
  • GPCR United States
  • AGX United States
  • Employees
  • GPCR N/A
  • AGX N/A
  • Industry
  • GPCR
  • AGX Engineering & Construction
  • Sector
  • GPCR
  • AGX Consumer Discretionary
  • Exchange
  • GPCR Nasdaq
  • AGX Nasdaq
  • Market Cap
  • GPCR 1.8B
  • AGX 2.1B
  • IPO Year
  • GPCR 2023
  • AGX N/A
  • Fundamental
  • Price
  • GPCR $34.17
  • AGX $136.64
  • Analyst Decision
  • GPCR Buy
  • AGX Strong Buy
  • Analyst Count
  • GPCR 5
  • AGX 2
  • Target Price
  • GPCR $86.80
  • AGX $77.50
  • AVG Volume (30 Days)
  • GPCR 677.5K
  • AGX 327.1K
  • Earning Date
  • GPCR 11-13-2024
  • AGX 12-04-2024
  • Dividend Yield
  • GPCR N/A
  • AGX 1.10%
  • EPS Growth
  • GPCR N/A
  • AGX 20.22
  • EPS
  • GPCR N/A
  • AGX 3.19
  • Revenue
  • GPCR N/A
  • AGX $713,006,000.00
  • Revenue This Year
  • GPCR N/A
  • AGX $35.03
  • Revenue Next Year
  • GPCR N/A
  • AGX $11.83
  • P/E Ratio
  • GPCR N/A
  • AGX $42.78
  • Revenue Growth
  • GPCR N/A
  • AGX 48.03
  • 52 Week Low
  • GPCR $26.61
  • AGX $39.74
  • 52 Week High
  • GPCR $66.38
  • AGX $162.78
  • Technical
  • Relative Strength Index (RSI)
  • GPCR 35.81
  • AGX 51.71
  • Support Level
  • GPCR $33.85
  • AGX $148.39
  • Resistance Level
  • GPCR $38.48
  • AGX $162.78
  • Average True Range (ATR)
  • GPCR 2.62
  • AGX 7.62
  • MACD
  • GPCR -0.36
  • AGX -1.28
  • Stochastic Oscillator
  • GPCR 3.67
  • AGX 27.01

About GPCR Structure Therapeutics Inc.

Structure Therapeutics Inc is a clinical-stage biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small-molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073 and LTSE-2578.

About AGX Argan Inc.

Argan Inc is a United States-base construction firm that conducts operations through its wholly-owned subsidiaries, GPS, APC, TRC and SMC. Through GPS and APC it provides a full range of engineering, procurement, construction, commissioning, maintenance, project development and technical consulting services to the power generation market, including the renewable energy sector, for a wide range of customers, including independent power project owners, public utilities, power plant heavy equipment suppliers and other commercial firms with power requirements in the U.S., Ireland and the U.K. It operates in three segments: Power Services, Industrial Services, and Telecom Services, out of which Power Services derive majority revenue.

Share on Social Networks: